[go: up one dir, main page]

WO2003037930A1 - Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same - Google Patents

Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same Download PDF

Info

Publication number
WO2003037930A1
WO2003037930A1 PCT/JP2002/011207 JP0211207W WO03037930A1 WO 2003037930 A1 WO2003037930 A1 WO 2003037930A1 JP 0211207 W JP0211207 W JP 0211207W WO 03037930 A1 WO03037930 A1 WO 03037930A1
Authority
WO
WIPO (PCT)
Prior art keywords
nr3a
gene encoding
glutamate receptor
nmda
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/011207
Other languages
French (fr)
Japanese (ja)
Other versions
WO2003037930A8 (en
Inventor
Hiroshi Mori
Osamu Ohara
Takahiro Nagase
Reiko Kikuno
Keiji Yamagami
Yoshitaka Ohashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kazusa DNA Research Institute Foundation
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Kazusa DNA Research Institute Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp, Kazusa DNA Research Institute Foundation filed Critical Mitsubishi Pharma Corp
Priority to JP2003540211A priority Critical patent/JPWO2003037930A1/en
Publication of WO2003037930A1 publication Critical patent/WO2003037930A1/en
Anticipated expiration legal-status Critical
Publication of WO2003037930A8 publication Critical patent/WO2003037930A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)

Abstract

It is intended to find out a novel substance relating to human NMDA glutamate receptor subunit 3A (NR3A). A novel cDNA originating in human brain is isolated and the full base sequence thereof is analyzed. Then this base sequence is translated into an amino acid sequence followed by homology searching. As a result, it is found out that this sequence has a 93% homology with rat NR3A and thus identified as human NR3A. Further, it is confirmed that a gene encoding NR3A is significantly increased in the brain of patients with schizophrenia. Thus, it is concluded that NR3A is a substance relating to the pathology of schizophrenia.
PCT/JP2002/011207 2001-10-29 2002-10-29 Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same Ceased WO2003037930A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003540211A JPWO2003037930A1 (en) 2001-10-29 2002-10-29 Novel human N-methyl-D-aspartate (NMDA) glutamate receptor polypeptide and gene encoding the same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001-331007 2001-10-29
JP2001331007 2001-10-29
JP2001-333258 2001-10-30
JP2001333258 2001-10-30
JP2001345262 2001-11-09
JP2001-345262 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003037930A1 true WO2003037930A1 (en) 2003-05-08
WO2003037930A8 WO2003037930A8 (en) 2004-06-03

Family

ID=27347747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/011207 Ceased WO2003037930A1 (en) 2001-10-29 2002-10-29 Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same

Country Status (2)

Country Link
JP (1) JPWO2003037930A1 (en)
WO (1) WO2003037930A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001044473A2 (en) * 1999-12-14 2001-06-21 Curagen Corporation Polypeptides and nucleic acids encoding same
WO2001081413A2 (en) * 2000-04-27 2001-11-01 Pe Corporation (Ny) Isolated human transporter proteins, nucleic acids and uses thereof
WO2002012340A2 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Transporters and ion channels
WO2002024743A2 (en) * 2000-09-19 2002-03-28 Millennium Pharmaceuticals, Inc. 55063, a human nmda family member and uses thereof
WO2002040538A2 (en) * 2000-11-17 2002-05-23 Bayer Aktiengesellschaft Regulation of human nmda receptor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001044473A2 (en) * 1999-12-14 2001-06-21 Curagen Corporation Polypeptides and nucleic acids encoding same
WO2001081413A2 (en) * 2000-04-27 2001-11-01 Pe Corporation (Ny) Isolated human transporter proteins, nucleic acids and uses thereof
WO2002012340A2 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Transporters and ion channels
WO2002024743A2 (en) * 2000-09-19 2002-03-28 Millennium Pharmaceuticals, Inc. 55063, a human nmda family member and uses thereof
WO2002040538A2 (en) * 2000-11-17 2002-05-23 Bayer Aktiengesellschaft Regulation of human nmda receptor

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANDERSSON O. ET AL.: "Nucleotide sequence, genomic organization and chromosomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B", GENOMICS, vol. 78, no. 3, December 2001 (2001-12-01), pages 178 - 184, XP002962975 *
DAS S. ET AL.: "Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A", NATURE, vol. 393, no. 6683, 28 May 1998 (1998-05-28), pages 377 - 381, XP002962970 *
ERIKSSON M. ET AL.: "Cloning and expression of the human N-methyl-D-aspartate receptor subunit NR3A", NEUROSCIENCE LETTERS, vol. 321, no. 3, 2002, pages 177 - 181, XP002962977 *
GOEBEL D.J. ET AL.: "NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A", MOL. BRAIN RES., vol. 69, no. 2, 8 June 1999 (1999-06-08), pages 164 - 170, XP002962971 *
PEREZ-OTANO I. ET AL.: "Assembly with the NR1 subunit is required for surface expression of NR3A-containing NMDA receptors", J. NEUROSCI., vol. 21, no. 4, 15 February 2001 (2001-02-15), pages 1228 - 1237, XP002962972 *
SASAKI Y.F. ET AL.: "Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons", J. NEUROPHYSIOL., vol. 87, no. 4, April 2002 (2002-04-01), pages 2052 - 2063, XP002962976 *
SUCHER N.J. ET AL.: "Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain", J. NEUROSCI., vol. 15, no. 10, October 1995 (1995-10-01), pages 6509 - 6520, XP001061256 *
TU S. ET AL.: "Generation of NR3A transgenic mice", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, pages 1850, XP002962974 *
VON EULER G. ET AL.: "Nucleotide sequence, genomic organization and chromosomal localization of the human NMDA receptor subunit NR3A", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, pages 920, XP002962973 *

Also Published As

Publication number Publication date
JPWO2003037930A1 (en) 2005-02-17
WO2003037930A8 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
BR0207325A (en) Therapeutic methods for diseases associated with decreased aop-1 or aop-1 gene expression
WO2003020932A1 (en) Novel secretory proteins and dna thereof
EP2298355A3 (en) Albumin fusion proteins
IS8622A (en) Method of Preparation of Polypeptide Preparations Using Purified Hydrochloric Acid
WO2005115306A3 (en) Keratin-binding polypeptides
AU5608000A (en) 22025, a novel human cyclic nucleotide phosphodiesterase
WO2004080957A3 (en) Use of adnf polypeptides for treating anxiety and depression
WO2002060923A3 (en) B-superfamily conotoxins
TR200503401T1 (en) Quetiapine new polymorphs of Fumarate
WO2003075944A3 (en) Interferon beta-like molecules for treatment of stroke
EP0816504A3 (en) Platelet activating factor acetylhdrolase, and gene thereof
WO2003037930A1 (en) Novel human n-methyl-d-asparatate (nmda) glutamate receptor polypeptide and gene encoding the same
WO2005042717A3 (en) Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods
AU2001232275A1 (en) Novel collagen-like protein clac, precursor thereof and genes encoding the same
AU3739500A (en) Protease resistant flint analogs
WO2002102847A1 (en) Novel ligand and dna thereof
AUPR775401A0 (en) Novel Epitopes and Uses Thereof
AU5909600A (en) 17867, a novel human aminopeptidase
DE602004019141D1 (en) ISOLEUCYL-VALYL-THREONYL-ASPARAGINYL-THREONYL-THREONIN (IVTNTT) CONTAINING BIODEGRADABLE PEPTIDES
WO2002008424A1 (en) Human and rat abca2 genes
WO2001090139A3 (en) A ligand for enhancing oral and cns delivery of biological agents
EP1634951A4 (en) Novel protein
WO2004113511A3 (en) Cell line and uses thereof
WO2001090141A3 (en) Gb1c isoform and nucleotides
AU4956901A (en) Novel human 7tm proteins and polynucleotides encoding the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003540211

Country of ref document: JP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 19/2003 UNDER (72, 75) DELETE "IRITANI, SHUJI [JP/JP]; ROOM 110, ABITASHION-ROKAKOUEN, 11-25, KASUYA 2-CHOME, SETAGAYA-KU, TOKYO 157-0063"; UNDER (71) ADD "IRITANI, SHUJI [JP/JP]; ROOM 110, ABITASHION-ROKAKOUEN, 11-25, KASUYA 2-CHOME, SETAGAYA-KU, TOKYO 157-0063"

122 Ep: pct application non-entry in european phase